| Literature DB >> 28507294 |
Haiyan Pan1, Tao Li2, Zhigang Huang1, Haibing Yu1, Danli Kong1, Yuanlin Ding1, Congcong Pan3, Yugang Jiang4.
Abstract
The aim of this study was to compare the outcomes of laparoscopic surgery (LAP) and open gastric surgery (OP) in early gastric cancer patients aged ≥70 years.We conducted a retrospectively analysis among patientswith pathological T1N0M0 gastric cancer,who underwent LAP or OP between January 1, 2001 and December 31, 2008. We identified a well-balanced cohort of 2,360 patients (1180 patients in each group). LAP has been shown to offer a superior perioperative results to OP, including lower blood loss, shorter time to oral intake, walk and bowel function recovery, shorter time of hospital stay, and less blood transfusion required. However, the intraoperative and postoperative complications, local recurrence, and metastasis didn't show statistically significant differences between groups. The 5-year overall survival (OS), disease-free survival (DFS), and cancer-specific survival (CSS) were 60.1% vs.63.2%, 80.8% vs. 83.3%, and 87.6% vs. 89.5% in the LAP group and OP group, respectively. The hazard ratios (HR) for OS, DFS, and CSS were 1.09(95% confidence interval [CI]: 0.95-1.25; P = 0.215), 1.03(95% CI: 0.91-1.18; P = 0.636), and 1.07 (95% CI: 0.88-1.30; P = 0.484), respectively, compared LAP group with OP group. In conclusion, LAP is an acceptable alternative to OP in elderly patients with early gastric cancer.Entities:
Year: 2017 PMID: 28507294 PMCID: PMC5432525 DOI: 10.1038/s41598-017-02182-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Rates of LAP and OP over time in patients with pathological stage T1N0M0 gastric cancer from the participating institutions.
Baseline demographics before and after propensity score matching.
| Variable | Overall (n = 4135) | After propensity score matching (n = 2360) | ||||
|---|---|---|---|---|---|---|
| Laparoscopic (n = 2139) | Open (n = 1996) | P value | Laparoscopic (n = 1180) | Open (n = 1180) | P value | |
| Age (y, mean ± SD) | 74.5 ± 7.2 | 73.2 ± 6.8 | < 0.001 | 73.9 ± 7.0 | 73.6 ± 6.9 | 0.295 |
| Sex (n, %) | ||||||
| Male | 1278 (59.7) | 1078 (54.0) | <0.001 | 702 (59.5) | 690 (58.5) | 0.616 |
| Female | 861 (40.3) | 918 (46.0) | 478 (40.5) | 490 (41.5) | ||
| ASA-PS (n, %) | ||||||
| 1 | 768 (35.9) | 621 (33.1) | 0.001 | 385 (32.6) | 362 (30.7) | 0.347 |
| 2 | 912 (42.6) | 868 (43.5) | 521 (44.2) | 556 (47.1) | ||
| 3 | 459 (21.5) | 507 (25.4) | 274 (23.2) | 262 (22.2) | ||
| BMI (kg/m2, mean ± SD) | 23.9 ± 10.3 | 23.1 ± 9.7 | 0.010 | 23.5 ± 7.4 | 23.4 ± 7.1 | 0.738 |
| Tumor size (mm, mean ± SD) | 37.6 ± 12.4 | 38.4 ± 11.5 | 0.033 | 37.9 ± 9.1 | 38.2 ± 9.3 | 0.428 |
| Tumor site (n, %) | ||||||
| Lower segment | 367 (17.2) | 274 (13.7) | <0.001 | 202 (17.1) | 195 (16.5) | 0.723 |
| Lower to middle segment | 149 (6.9) | 101 (5.1) | 89 (7.5) | 73 (6.2) | ||
| Middle segment | 806 (37.7) | 735 (36.8) | 427 (36.2) | 438 (37.1) | ||
| Middle to upper segment | 235 (11.0) | 241 (12.1) | 156 (13.2) | 164 (13.9) | ||
| Upper segment | 582 (27.2) | 645 (32.3) | 306 (26.0) | 310 (26.3) | ||
| Previous abdominal surgery (n, %) | 234 (10.9) | 193 (9.7) | 0.180 | 119 (10.1) | 113 (9.6) | 0.678 |
| Tumor stage (n, %) | ||||||
| T1aN0M0 | 1455 (68.0) | 1419 (71.1) | 0.032 | 824 (69.8) | 833 (70.6) | 0.685 |
| T1bN0M0 | 684 (32.0) | 577 (28.9) | 356 (30.2) | 347 (29.4) | ||
| Tumor grade (n, %) | ||||||
| 1 | 599 (28.0) | 486 (24.3) | 0.056 | 312 (26.5) | 298 (25.3) | 0.788 |
| 2 | 933 (43.6) | 928 (46.5) | 535 (45.3) | 554 (46.9) | ||
| 3 | 545 (25.5) | 527 (26.4) | 305 (25.8) | 296 (25.1) | ||
| Unclassified | 62 (2.9) | 55 (2.8) | 28 (2.4) | 32 (2.7) | ||
| Histopathological type (n, %) | ||||||
| Papillary adenocarcinoma | 651 (30.4) | 496 (24.8) | <0.001 | 349 (29.6) | 317 (26.9) | 0.219 |
| Tubular adenocarcinoma | 507 (23.7) | 568 (28.5) | 286 (24.2) | 326 (27.6) | ||
| Poorly differentiated adenocarcinoma | 296 (13.8) | 281 (14.1) | 166 (14.1) | 174 (14.7) | ||
| Mucinous adenocarcinoma | 359 (16.8) | 392 (19.6) | 212 (18.0) | 223 (18.9) | ||
| Signet-ring cell carcinoma | 215 (10.1) | 163 (8.2) | 115 (9.7) | 95 (8.1) | ||
| Others | 111 (5.2) | 96 (4.8) | 52 (4.4) | 45 (3.8) | ||
| Lauren’s type (n, %) | ||||||
| Intestinal | 1222 (57.1) | 1097 (55.0) | <0.001 | 670 (56.8) | 647 (54.8) | 0.149 |
| Diffuse | 813 (38.0) | 734 (36.8) | 450 (38.1) | 451 (38.2) | ||
| Mixed | 104 (4.9) | 165 (8.2) | 60 (5.1) | 82 (7.0) | ||
| Local extent of gastric resection (n, %) | ||||||
| Subtotal gastrectomy | 1960 (91.6) | 1800 (90.2) | 0.104 | 1072 (90.8) | 1063 (90.1) | 0.528 |
| Total gastrectomy | 179 (8.4) | 196 (9.8) | 108 (9.2) | 117 (9.9) | ||
| Surgical margins (n, %) | ||||||
| Negative | 1887 (88.2) | 1716 (86.0) | 0.031 | 1027 (87.0) | 1016 (86.1) | 0.507 |
| Positive | 252 (11.8) | 280 (14.0) | 153 (13.0) | 164 (13.9) | ||
| Postoperative chemotherapy(n, %) | ||||||
| Yes | 93 (4.3) | 96 (4.8) | 0.019 | 53 (4.5) | 56 (4.7) | 0.714 |
| No | 1905 (89.1) | 1808 (90.6) | 1052 (89.2) | 1058 (89.7) | ||
| Unknown | 141 (6.6) | 92 (4.6) | 75 (6.3) | 66 (5.6) | ||
| Postoperative radiotherapy(n, %) | ||||||
| Yes | 142 (6.6) | 157 (7.9) | 0.099 | 81 (6.9) | 86 (7.3) | 0.514 |
| No | 1928 (90.2) | 1791 (89.7) | 1060 (89.8) | 1064 (90.2) | ||
| Unknown | 69 (3.2) | 48 (2.4) | 39 (3.3) | 30 (2.5) | ||
ASA-PS, American Society of Anesthesiologists physical status; BMI, body mass index; SD, standard deviation.
Intraoperative and postoperative results.
| Variable | Laparoscopic (n = 1180) | Open (n = 1180) | P value |
|---|---|---|---|
| Follow-up duration (mo, mean ± SD) | 59.6 ± 11.4 | 60.4 ± 12.6 | 0.106 |
| Operative time (min, mean ± SD) | 263.2 ± 58.7 | 184.5 ± 49.1 | <0.001 |
| Estimated blood loss (ml, mean ± SD) | 149 ± 155 | 263 ± 232 | <0.001 |
| Number of lymph node dissection (mean ± SD) | 27.3 ± 3.5 | 27.1 ± 3.1 | 0.142 |
| Number of positive lymph nodes (mean ± SD) | 8.4 ± 2.6 | 8.3 ± 2.4 | 0.332 |
| Time to oral intake after surgery (d, mean ± SD) | 2.3 ± 0.9 | 3.3 ± 1.2 | <0.001 |
| Time to walk after surgery (d, mean ± SD) | 1.4 ± 0.5 | 2.7 ± 1.0 | <0.001 |
| Time to bowel function recovery (d, mean ± SD)* | 2.1 ± 0.4 | 2.8 ± 0.7 | <0.001 |
| Postoperative hospital stay (d, mean ± SD) | 11.2 ± 2.3 | 13.6 ± 2.9 | <0.001 |
| Blood transfusion required (n, %) | 213 (18.1) | 347 (29.4) | <0.001 |
| Intraoperative complications (n, %) | 102 (8.6) | 113 (9.6) | 0.431 |
| Postoperative complications, ≥grade 3 (n, %)** | 149 (12.6) | 167 (14.2) | 0.277 |
| Local recurrence (n, %) | 153 (13.0) | 146 (12.4) | 0.665 |
| Metastasis (n, %) | 102 (8.6) | 97 (8.2) | 0.711 |
| Number of patients undergoing a curative second resection (n, %) | 104 (8.8) | 93 (7.9) | 0.413 |
SD, standard deviation.
*Defined as time of anal exhaust or defecation.
**According to the Clavien-Dindo classification.
Results of complications and metastasis.
| Variable (n, %) | Laparoscopic (n = 1180) | Open (n = 1180) | P value |
|---|---|---|---|
| Intraoperative complications | |||
| Vascularhemorrhage | 53 (4.5) | 42 (3.6) | 0.249 |
| Surgical injuries | 39 (3.3) | 54 (4.6) | 0.113 |
| Others | 18 (1.5) | 27 (2.3) | 0.176 |
| Postoperative complications (≥grade 3)* | |||
| Short-term problems | |||
| Intra-abdominal bleeding | 22 (1.9) | 28 (2.4) | 0.391 |
| Intraluminal bleeding | 42 (3.6) | 48 (4.1) | 0.519 |
| Anastomotic leakage | 24 (2.0) | 21 (1.8) | 0.652 |
| Pancreatic fistula | 18 (1.5) | 25 (2.1) | 0.281 |
| Abdominal abscess or fluid collection | 6 (0.5) | 8 (0.7) | 0.592 |
| Wound infection | 2 (0.2) | 6 (0.5) | 0.288 |
| Stenosis | 7 (0.6) | 10 (0.8) | 0.465 |
| Enteroparalysis | 9 (0.8) | 12 (1.0) | 0.511 |
| Ascites | 1 (0.1) | 4 (0.3) | 0.371 |
| Pneumonia | 4 (0.3) | 7 (0.6) | 0.365 |
| Cardiac problem | 2 (0.2) | 1 (0.1) | 1.000 |
| Neurological problem | 0 (0.0) | 0 (0.0) | — |
| Others | 7 (0.6) | 12 (1.0) | 0.249 |
| Long-term problems | |||
| Small bowel obstruction | 12 (1.0) | 31 (2.6) | 0.003 |
| Internal hernia | 1 (0.1) | 3 (0.3) | 0.617 |
| Postoperative metastasis site | |||
| Lymph node | 41 (3.4) | 32 (2.7) | 0.285 |
| Ovary** | 27 (5.5) | 18 (3.8) | 0.197 |
| Liver | 29 (2.5) | 26 (2.2) | 0.682 |
| Lung | 23 (1.9) | 19 (1.6) | 0.533 |
| Peritoneum | 12 (1.0) | 25 (2.1) | 0.031 |
| Brain | 15 (1.3) | 11 (0.9) | 0.430 |
| Bone | 8 (0.7) | 11 (0.9) | 0.490 |
| Others | 13 (1.1) | 9 (0.8) | 0.392 |
*According to the Clavien-Dindo classification.
**Calculated and compared only in female patients.
Figure 2Overall survival rate (A), disease-free survival rate (B), and cancer-specific survival rate (C) in LAP and OP.